Details of the Drug Combination

General Information of Drug Combination (ID: DCS10DY)

Drug Combination Name
Oxilan iohexol AMINOHIPPURIC ACID
Indication
Disease Entry Status REF
Type 2 Diabetes Mellitus Phase 1 [1]
Component Drugs Oxilan iohexol   DMKQF4U AMINOHIPPURIC ACID   DMUN54G
N.A. Small molecular drug
2D MOL 2D MOL
3D Structure is Not Available
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Oxilan iohexol
Disease Entry ICD 11 Status REF
Vascular disease BE2Z Approved [2]
Indication(s) of AMINOHIPPURIC ACID
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [3]
AMINOHIPPURIC ACID Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Solute carrier family 22 member 8 (SLC22A8) TTTQR47 S22A8_HUMAN Inhibitor [9]
------------------------------------------------------------------------------------
AMINOHIPPURIC ACID Interacts with 9 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [10]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [10]
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [11]
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [12]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [13]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [14]
ATP-binding cassette sub-family A member 8 (ABCA8) DT9NXMV ABCA8_HUMAN Substrate [15]
Sodium-dependent phosphate transport protein 3 (SLC17A2) DTRF4L3 NPT3_HUMAN Substrate [16]
Sodium-dependent phosphate transport protein 4 (SLC17A3) DTFOJL7 NPT4_HUMAN Substrate [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DTP(s)
AMINOHIPPURIC ACID Interacts with 98 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
ABC-type organic anion transporter ABCA8 (ABCA8) OTCWLX6N ABCA8_HUMAN Affects Transport [15]
Sodium-dependent phosphate transport protein 4 (SLC17A3) OTMJWIBM NPT4_HUMAN Affects Transport [18]
Organic anion transporter 3 (SLC22A8) OT8BY933 S22A8_HUMAN Increases Uptake [19]
Aryl hydrocarbon receptor repressor (AHRR) OTSJ12W6 AHRR_HUMAN Decreases Expression [20]
Secretory carrier-associated membrane protein 3 (SCAMP3) OTUNPYCE SCAM3_HUMAN Affects Expression [5]
Glutathione S-transferase A4 (GSTA4) OTZ1USIA GSTA4_HUMAN Affects Expression [21]
C-X-C motif chemokine 13 (CXCL13) OT2AT4N8 CXL13_HUMAN Affects Expression [5]
Pre-mRNA-processing factor 17 (CDC40) OTOYUNHN PRP17_HUMAN Affects Expression [21]
Glutathione reductase, mitochondrial (GSR) OTM2TUYM GSHR_HUMAN Affects Expression [21]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Increases Expression [22]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Expression [22]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Increases Expression [23]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Increases Expression [4]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Increases Expression [24]
Annexin A1 (ANXA1) OT5OFDJC ANXA1_HUMAN Affects Expression [5]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Decreases Methylation [25]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Expression [26]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Increases Expression [23]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Increases Expression [27]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [4]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Phosphorylation [22]
Tyrosine-protein kinase Fyn (FYN) OTLSLVZS FYN_HUMAN Increases Activity [6]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [4]
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) OTREV92I CEAM5_HUMAN Affects Expression [5]
Tyrosine-protein kinase Lyn (LYN) OTP686K2 LYN_HUMAN Affects Expression [5]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Affects Expression [5]
Glutathione S-transferase A2 (GSTA2) OTW7UB1H GSTA2_HUMAN Affects Expression [21]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [28]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [22]
Fibroblast growth factor 6 (FGF6) OTRJ679P FGF6_HUMAN Increases Expression [4]
Alcohol dehydrogenase class-3 (ADH5) OTSO67MI ADHX_HUMAN Affects Expression [21]
Cyclic AMP-dependent transcription factor ATF-2 (ATF2) OTNIZPEA ATF2_HUMAN Increases Phosphorylation [22]
Fos-related antigen 1 (FOSL1) OT9YTYMB FOSL1_HUMAN Increases Expression [4]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Decreases Methylation [29]
Integrin beta-5 (ITGB5) OT21MF51 ITB5_HUMAN Affects Expression [5]
Syndecan-1 (SDC1) OTWKRVZC SDC1_HUMAN Affects Expression [5]
Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) OTDS2EAR TNR1B_HUMAN Increases Expression [30]
Proteasome subunit beta type-1 (PSMB1) OTYRFBAH PSB1_HUMAN Affects Expression [21]
Interleukin-11 (IL11) OTXHN86R IL11_HUMAN Increases Expression [4]
Amine oxidase A (MAOA) OT8NIWMQ AOFA_HUMAN Affects Expression [21]
Catechol O-methyltransferase (COMT) OTPWKTQG COMT_HUMAN Affects Expression [20]
Interleukin-10 (IL10) OTIRFRXC IL10_HUMAN Decreases Expression [31]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [22]
Proteasome subunit alpha type-1 (PSMA1) OTNBVM2U PSA1_HUMAN Affects Expression [21]
Protein S100-A4 (S100A4) OTLRGFSQ S10A4_HUMAN Affects Expression [5]
Amine oxidase B (MAOB) OTTDFM1O AOFB_HUMAN Affects Expression [21]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [28]
Aryl hydrocarbon receptor nuclear translocator (ARNT) OTMSIEZY ARNT_HUMAN Increases Expression [24]
Proteasome subunit alpha type-5 (PSMA5) OT38E6Y1 PSA5_HUMAN Affects Expression [21]
Proteasome subunit beta type-5 (PSMB5) OTOZXAS6 PSB5_HUMAN Affects Expression [21]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [28]
Interleukin-12 subunit alpha (IL12A) OTDQT8GI IL12A_HUMAN Decreases Expression [31]
Ribonucleoside-diphosphate reductase subunit M2 (RRM2) OTOB6J6R RIR2_HUMAN Affects Expression [21]
Fibroblast growth factor 9 (FGF9) OT2SKDGM FGF9_HUMAN Increases Expression [4]
Interleukin-13 (IL13) OTI4YS3Y IL13_HUMAN Increases Expression [23]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Increases Expression [20]
26S proteasome regulatory subunit 7 (PSMC2) OTJ4V337 PRS7_HUMAN Affects Expression [21]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [4]
N-alpha-acetyltransferase 10 (NAA10) OTYB9R6I NAA10_HUMAN Affects Expression [21]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [20]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Increases Phosphorylation [28]
Mitogen-activated protein kinase 9 (MAPK9) OTCEVJ9E MK09_HUMAN Increases Phosphorylation [28]
Dual specificity mitogen-activated protein kinase kinase 4 (MAP2K4) OTZPZX11 MP2K4_HUMAN Increases Phosphorylation [22]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Affects Expression [21]
Glutamate--cysteine ligase regulatory subunit (GCLM) OT6CP234 GSH0_HUMAN Affects Expression [21]
Proteasome subunit beta type-3 (PSMB3) OTVBON40 PSB3_HUMAN Affects Expression [21]
Methionine aminopeptidase 2 (METAP2) OTNDI7YK MAP2_HUMAN Affects Expression [5]
26S proteasome non-ATPase regulatory subunit 4 (PSMD4) OTH1VZTM PSMD4_HUMAN Affects Expression [21]
T-cell leukemia/lymphoma protein 1A (TCL1A) OTPRVZQM TCL1A_HUMAN Affects Expression [5]
26S proteasome regulatory subunit 4 (PSMC1) OTLHD56E PRS4_HUMAN Affects Expression [21]
Nuclear factor NF-kappa-B p100 subunit (NFKB2) OTS231V7 NFKB2_HUMAN Increases Expression [24]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Affects Expression [21]
Serine/arginine-rich splicing factor 1 (SRSF1) OTF61HOV SRSF1_HUMAN Affects Expression [21]
FAS-associated death domain protein (FADD) OTV7GFHH FADD_HUMAN Affects Expression [5]
Interleukin-27 subunit beta (EBI3) OT0LF3D7 IL27B_HUMAN Decreases Expression [31]
Transmembrane glycoprotein NMB (GPNMB) OTB7KQKV GPNMB_HUMAN Affects Expression [5]
Splicing factor 3B subunit 3 (SF3B3) OTAC9LZT SF3B3_HUMAN Affects Expression [21]
Serine/arginine-rich splicing factor 7 (SRSF7) OTRS4W4S SRSF7_HUMAN Affects Expression [21]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Expression [32]
Glutathione S-transferase A3 (GSTA3) OTJ3REE3 GSTA3_HUMAN Affects Expression [21]
Heterogeneous nuclear ribonucleoprotein A1-like 2 (HNRNPA1L2) OTNJ7OTE RA1L2_HUMAN Affects Expression [21]
PHD finger-like domain-containing protein 5A (PHF5A) OTS94JFM PHF5A_HUMAN Affects Expression [21]
Pre-mRNA-splicing factor 38A (PRPF38A) OT88097H PR38A_HUMAN Affects Expression [21]
26S proteasome non-ATPase regulatory subunit 1 (PSMD1) OTW258OV PSMD1_HUMAN Affects Expression [21]
Forkhead box protein P3 (FOXP3) OTA9Z9OC FOXP3_HUMAN Increases Methylation [23]
Sulfotransferase 1A1 (SULT1A1) OT0K7JIE ST1A1_HUMAN Affects Metabolism [33]
Solute carrier family 22 member 11 (SLC22A11) OTAJLNJZ S22AB_HUMAN Increases Export [34]
Epoxide hydrolase 1 (EPHX1) OTBKWQER HYEP_HUMAN Decreases Metabolism [35]
Arylamine N-acetyltransferase 2 (NAT2) OTBPDQOY ARY2_HUMAN Increases Acetylation [33]
Arylamine N-acetyltransferase 1 (NAT1) OTCCNQ3H ARY1_HUMAN Increases Acetylation [33]
Serum paraoxonase/arylesterase 1 (PON1) OTD0Z2XO PON1_HUMAN Increases Response To Substance [36]
Solute carrier family 22 member 7 (SLC22A7) OTKTNH1W S22A7_HUMAN Increases Uptake [37]
Glutathione S-transferase Mu 3 (GSTM3) OTLA2WJT GSTM3_HUMAN Increases Response To Substance [38]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Increases Metabolism [35]
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Affects Response To Substance [39]
Glutathione S-transferase theta-1 (GSTT1) OTRFMWBK GSTT1_HUMAN Decreases Activity [33]
Glutathione S-transferase Mu 1 (GSTM1) OTSBF2MO GSTM1_HUMAN Increases Response To Substance [40]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Affects Response To Substance [41]
------------------------------------------------------------------------------------
⏷ Show the Full List of 98 DOT(s)

References

1 ClinicalTrials.gov (NCT03584217) Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4810).
4 Induction of fibroblast growth factor-9 and interleukin-1alpha gene expression by motorcycle exhaust particulate extracts and benzo(a)pyrene in human lung adenocarcinoma cells. Toxicol Sci. 2005 Oct;87(2):483-96. doi: 10.1093/toxsci/kfi251. Epub 2005 Jul 7.
5 Cancer-related proteins in serum are altered in workers occupationally exposed to polycyclic aromatic hydrocarbons: a cross-sectional study. Carcinogenesis. 2019 Jul 6;40(6):771-781. doi: 10.1093/carcin/bgz022.
6 Protein tyrosine kinase activation by polycyclic aromatic hydrocarbons in human HPB-ALL T cells. J Toxicol Environ Health A. 1999 Feb 26;56(4):249-61. doi: 10.1080/009841099158097.
7 Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis. Pharmacogenet Genomics. 2011 Feb;21(2):55-65. doi: 10.1097/FPC.0b013e328341db05.
8 Interactions between exposure to environmental polycyclic aromatic hydrocarbons and DNA repair gene polymorphisms on bulky DNA adducts in human sperm. PLoS One. 2010 Oct 5;5(10):e13145. doi: 10.1371/journal.pone.0013145.
9 Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53.
10 ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int. 2000 Apr;57(4):1636-42.
11 Contribution of multidrug resistance protein 2 (MRP2/ABCC2) to the renal excretion of p-aminohippurate (PAH) and identification of MRP4 (ABCC4) as a novel PAH transporter. J Am Soc Nephrol. 2004 Nov;15(11):2828-35.
12 Interactions of human organic anion transporter 1 (hOAT1) with substances associated with forensic toxicology. Leg Med (Tokyo). 2011 Jul;13(4):180-5.
13 Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
14 Characterization and identification of steroid sulfate transporters of human placenta. Am J Physiol Endocrinol Metab. 2003 Feb;284(2):E390-8.
15 Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5.
16 Wide expression of type I Na+-phosphate cotransporter 3 (NPT3/SLC17A2), a membrane potential-driven organic anion transporter. Am J Physiol Cell Physiol. 2015 Jul 15;309(2):C71-80.
17 Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem. 2010 Nov 5;285(45):35123-32.
18 Functional analysis of human sodium-phosphate transporter 4 (NPT4/SLC17A3) polymorphisms. J Pharmacol Sci. 2011;115(2):249-53. doi: 10.1254/jphs.10228sc. Epub 2011 Jan 26.
19 Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13.
20 Effects of human blood levels of two PAH mixtures on the AHR signalling activation pathway and CYP1A1 and COMT target genes in granulosa non-tumor and granulosa tumor cell lines. Toxicology. 2017 Aug 15;389:1-12. doi: 10.1016/j.tox.2017.07.003. Epub 2017 Jul 11.
21 Identification of molecular signatures predicting the carcinogenicity of polycyclic aromatic hydrocarbons (PAHs). Toxicol Lett. 2012 Jul 7;212(1):18-28. doi: 10.1016/j.toxlet.2012.04.013. Epub 2012 May 1.
22 Nanomolar levels of PAHs in extracts from urban air induce MAPK signaling in HepG2 cells. Toxicol Lett. 2014 Aug 17;229(1):25-32. doi: 10.1016/j.toxlet.2014.06.013. Epub 2014 Jun 6.
23 Childhood exposure to ambient polycyclic aromatic hydrocarbons is linked to epigenetic modifications and impaired systemic immunity in T cells. Clin Exp Allergy. 2015 Jan;45(1):238-48. doi: 10.1111/cea.12377.
24 Compounds of PAH mixtures dependent interaction between multiple signaling pathways in granulosa tumour cells. Toxicol Lett. 2019 Aug;310:14-22. doi: 10.1016/j.toxlet.2019.04.008. Epub 2019 Apr 10.
25 Shorter telomere length in peripheral blood lymphocytes of workers exposed to polycyclic aromatic hydrocarbons. Carcinogenesis. 2010 Feb;31(2):216-21. doi: 10.1093/carcin/bgp278. Epub 2009 Nov 5.
26 Effect of artificial mixtures of environmental polycyclic aromatic hydrocarbons present in coal tar, urban dust, and diesel exhaust particulates on MCF-7 cells in culture. Environ Mol Mutagen. 2004;44(2):99-107. doi: 10.1002/em.20039.
27 Influence of cigarette smoking on melatonin levels in man. Eur J Clin Pharmacol. 2005 May;61(3):197-201. doi: 10.1007/s00228-005-0908-7. Epub 2005 Apr 12.
28 Differential proinflammatory responses induced by diesel exhaust particles with contrasting PAH and metal content. Environ Toxicol. 2015 Feb;30(2):188-96. doi: 10.1002/tox.21884. Epub 2013 Jul 31.
29 Global and MGMT promoter hypomethylation independently associated with genomic instability of lymphocytes in subjects exposed to high-dose polycyclic aromatic hydrocarbon. Arch Toxicol. 2013 Nov;87(11):2013-2022. doi: 10.1007/s00204-013-1046-0. Epub 2013 Mar 30.
30 Association of biomarkers of systemic inflammation with organic components and source tracers in quasi-ultrafine particles. Environ Health Perspect. 2010 Jun;118(6):756-62. doi: 10.1289/ehp.0901407. Epub 2010 Feb 2.
31 The impact on T-regulatory cell related immune responses in rural women exposed to polycyclic aromatic hydrocarbons (PAHs) in household air pollution in Gansu, China: A pilot investigation. Environ Res. 2019 Jun;173:306-317. doi: 10.1016/j.envres.2019.03.053. Epub 2019 Mar 26.
32 Occupational exposure to polycyclic aromatic hydrocarbons suppresses constitutive expression of CYP1B1 on the transcript level in human leukocytes. Int J Hyg Environ Health. 2004 Sep;207(4):325-35. doi: 10.1078/1438-4639-00298.
33 GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer. 2004 Jul 1;110(4):598-604. doi: 10.1002/ijc.20157.
34 Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy. Toxicology. 2009 Oct 1;264(1-2):74-9. doi: 10.1016/j.tox.2009.07.014. Epub 2009 Jul 28.
35 Occupational exposure to polycyclic aromatic hydrocarbons in German industries: association between exogenous exposure and urinary metabolites and its modulation by enzyme polymorphisms. Toxicol Lett. 2005 Jul 4;157(3):241-55. doi: 10.1016/j.toxlet.2005.02.012. Epub 2005 Apr 8.
36 [Effects of oxidative DNA damage induced by polycyclic aromatic hydrocarbons and genetic polymorphism of the paraoxonase-1 (PON1) gene on lung cancer]. J Prev Med Public Health. 2005 Aug;38(3):345-50.
37 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
38 A case-control study of microsomal epoxide hydrolase, smoking, meat consumption, glutathione S-transferase M3, and risk of colorectal adenomas. Cancer Res. 2001 Mar 15;61(6):2381-5.
39 Modulation of DNA repair capacity by ataxia telangiectasia mutated gene polymorphisms among polycyclic aromatic hydrocarbons-exposed workers. Toxicol Sci. 2011 Nov;124(1):99-108. doi: 10.1093/toxsci/kfr216. Epub 2011 Aug 26.
40 Glutathione-S-transferase M1, M3, T1 and P1 polymorphisms and susceptibility to non-small-cell lung cancer subtypes and hamartomas. Pharmacogenetics. 2001 Dec;11(9):757-64. doi: 10.1097/00008571-200112000-00003.
41 [A study on the inherited susceptibility of chromosomal damage in peripheral blood lymphocytes among coke oven workers]. Zhonghua Yu Fang Yi Xue Za Zhi. 2004 Mar;38(2):94-8.